Recent Updates
Recently added Catalysts

SRX Global Inc.

SRXHFDA catalysts, PDUFA dates & pipeline intelligence
$1.03
▲ +0.03 · +3%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SRXH financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.8552W HIGH $42.61
Volume
1.14 M
Value Traded
1.22 M
Short % Float
5.05%
Days to Cover
2.3
-2.88%Week
-37.27%1 Month
-29.86%3 Month
-85.38%6 Month
-100%5 Year
-100%All Time

Cash Data

Unlock SRXH cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
20.87 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-23.81 M
Total Shares
20.27 M
Float Shares
19.77 M
Insiders
2.07%
Institutions
7.30%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every SRXH catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SRXH Catalyst Timeline

Dated clinical, regulatory and corporate events for SRX Global Inc.

Unlock the full SRXH catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SRXH actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all SRXH historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the SRXH pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every SRXH program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every SRXH trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SRXH insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
White David AllanDirectorBuy 69,732 69,732 held$0.62 07/07/2025
Unlock the full SRXH insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in SRXH for Q3 2026.
Unlock every fund holding SRXH
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SRXH
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SRXH ownership
Insider and institutional ownership, quarter by quarter.

SRXH Short Interest

Shares sold short, counted twice a month.

5.05%
Short % of Float
of tradable shares sold short
998.5K
Shares Sold Short
-47.7% vs prior count
2.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
434.3K
Avg Daily Volume
the average used for days to cover
Unlock SRXH short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock SRXH option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SRXH option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SRXH options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SRXH ranks across every disease it competes in

Competitive Position is a premium feature
See how SRXH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SRXH News

SRXH
Nov 20, 2026
SRXHGeneral
▲ +3%today

SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement

SRX Global announced updates on its engineered T-cell strategy following Pfizer's $330 million licensing deal with Starna Therapeutics. The company is set to acquire CERo Therapeutics, which is advancing its CER-1236 therapy in a Phase 1/1b trial. Initial results show no dose-limiting toxicities, supporting the therapy's safety profile.

Read more →
SRXH
Oct 30, 2026
SRXHGeneral
▲ +7.4%on this news

SRX Global Provides Update on Balance Sheet and Share Buyback

SRX Global Inc. reported a balance sheet update, revealing approximately $34 million in cash and equivalents. The company is actively utilizing a stock repurchase program, allowing for up to 10 million shares to be repurchased. Fiscal year-end results are expected to be reported in early December 2026.

Read more →
SRXH
Oct 26, 2026
SRXHPhases

SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

SRX Global has activated UC Davis as a clinical trial site for the Phase 1 CERTAIN-T study of CER-1236 in hematologic malignancies. This activation aims to enhance patient recruitment and streamline treatment logistics. The study has shown promising safety profiles, with no dose-limiting toxicities reported in the second cohort. The trial has expanded to include additional hematologic conditions.

Read more →
SRXH
Oct 8, 2026
SRXHGeneral
▼ -6%on this news

SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform

SRX Global Inc. announced a $2.5 million investment to launch a multi-strategy trading platform in partnership with 5T Trading. The initiative aims to support the next generation of proprietary traders under the leadership of Eric Jackson. This venture is part of SRX's strategy to invest in high-conviction assets and generate long-term shareholder value.

Read more →
SRXH
Oct 7, 2026
SRXHGeneral

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

SRX Global has entered a definitive agreement to acquire CERo Therapeutics, enhancing its oncology portfolio. This acquisition aims to expedite the development of CERo's lead candidate, CER-1236, for hematologic malignancies. The deal is anticipated to provide CERo with better access to capital and operational resources.

Read more →
SRXH
Oct 6, 2026
SRXHGeneral

SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim

SRX Global announced a $1.5 million investment to launch a family of AI-powered ETFs via its EMJX platform. The first ETF will focus on actively managing digital asset volatility and is expected to be available in Q1 2027. The company plans to dividend ETF holdings directly to shareholders, enhancing shareholder value.

Read more →
SRXH
Sep 24, 2026
SRXHGeneral

SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)

SRX Global Inc. announced an update on its portfolio, liquidating holdings in Vistagen Therapeutics and Greenland Mines. The company has invested in Onconetix, which is set to acquire Realbotix LLC. The Vinci AI Vision system from Realbotix is noted for its innovative technology in robotics.

Read more →
SRXH
Sep 23, 2026
SRXHConferences/Events

SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar

SRX Global Inc. will have its CEO Kent Cunningham and President Eric Jackson present at the Webull Corporate Connect Series Fintech Investment Webinar on September 30, 2026. The webinar aims to engage investors and discuss the company's strategic focus on long-term shareholder value through AI-driven investments. Registration is available on the Webull platform.

Read more →
SRXH
Sep 3, 2026
SRXHPhases

SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company

SRX Global Inc. provided a shareholder update on its portfolio company ARMR Sciences, highlighting the successful immune response generated by ARMR-100 against fentanyl in clinical trials. The company also announced a contract with the Department of War to develop medical countermeasures and received FDA acceptance into the Model Informed Drug Development program. These developments indicate strong progress and regulatory momentum for ARMR's initiatives.

Read more →
SRXH
Aug 31, 2026
SRXHPhases

SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers

SRX Global has acquired senior secured debt in CERo Therapeutics to support the development of CER-1236, an innovative treatment for hematologic cancers. This investment aims to enhance CERo's clinical programs, particularly the ongoing Phase 1 CERTAIN-T trial. The trial has shown promising results, with no dose-limiting toxicities reported.

Read more →
SRXH
Aug 13, 2026
SRXHGeneral

SRX Global Inc. Announces Fiscal Third Quarter 2026 Financial Results

SRX Global Inc. reported its fiscal third quarter 2026 results, revealing a 27% increase in net sales to $3.4 million. The adjusted EBITDA loss improved by 35% year over year, and the company ended the quarter with $36.7 million in cash and no debt. Additionally, SRX completed the acquisition of EMJX, enhancing its investment strategy.

Read more →
SRXH
Aug 6, 2026
SRXHConferences/Events

SRX Global to Host Fiscal Third Quarter 2026 Conference Call on August 13 at 4:30 p.m. ET

SRX Global Inc. announced its upcoming conference call to discuss financial results for the fiscal third quarter ending June 30, 2026. The call is scheduled for August 13, 2026, at 4:30 p.m. ET. Interested parties can access a recording on the investor relations website, and a Q&A session will follow the presentation.

Read more →
SRXH
Jul 30, 2026
SRXHGeneral
▼ -9.2%on this news

SRX Global Acquires Shares in Jersey Mike’s $1 Billion Initial Public Offering

SRX Global Inc. has announced its acquisition of shares in the initial public offering of Jersey Mike's, which is valued at $1 billion. The IPO priced its Class A common shares at $23.00 each and began trading on the NYSE under the ticker JMKE. SRX Global aims to generate long-term shareholder value through strategic investments.

Read more →
SRXH
Jul 9, 2026
SRXHGeneral
▲ +40.6%on this news

SRX Global Board of Directors Authorizes Stock Repurchase Plan of Up to 10 Million Shares or Up to 50% of its Shares Outstanding

SRX Global Inc. has authorized a share repurchase program allowing for the buyback of up to 10 million shares, representing 50% of its outstanding shares. The company plans to allocate $20 million for this initiative, which reflects its strong cash position and confidence in its long-term strategy. The repurchase may occur through various methods, depending on market conditions.

Read more →
SRXH
Jul 2, 2026
SRXHGeneral
▼ -66.6%on this newsshared move

SRX Global Makes Strategic Investment in Critical and Precious Minerals Development Company, Greenland Mines

SRX Global, Inc. has announced a strategic investment in Greenland Mines Ltd., a company focused on critical and precious minerals development in Greenland. This investment aims to enhance SRX's portfolio and support the development of a multi-asset platform that includes rare earth materials and precious metals. Greenland Mines is working towards linking Greenland's resources with industrial infrastructure in allied jurisdictions.

Read more →
SRXH
Jun 24, 2026
SRXHGeneral
▼ -66.6%on this newsshared move

SRX Global Announces Share Consolidation

SRX Global, Inc. announced a 60-to-1 share consolidation effective July 6, 2026. This move is expected to streamline the company's stock structure and enhance shareholder value. The common stock will continue to trade under the symbol 'SRXH' and will adopt a new CUSIP number. Shareholders will receive whole shares in lieu of any fractional shares.

Read more →
SRXH
Jun 23, 2026
SRXHGeneral
▼ -18.7%on this news· ran to -73% by day 1shared move

SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences

SRX Global has made a strategic investment in ARMR Sciences, a clinical-stage company focused on developing medical countermeasures against synthetic drugs like fentanyl. ARMR's lead product, ARMR-100, has shown success in generating an anti-fentanyl immune response in humans. The next phase of trials is set to evaluate its effectiveness against fentanyl, aiming for a long-lasting preventive solution.

Read more →
SRXH
Jun 18, 2026
SRXHGeneral
▼ -37.6%on this news· ran to -85% by day 3shared move

SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets

SRx Health Solutions has completed the acquisition of EMJ Crypto Technologies, rebranding as SRX Global. The company will focus on an AI-driven strategy for capital allocation into high-potential assets. CEO Kent Cunningham emphasized the synergies between the two firms, aiming to enhance shareholder returns. The stock will continue trading under the ticker SRXH.

Read more →
SRXH
Jun 8, 2026
SRXHGeneral

SRx Health Solutions Acquires 4.99% of Smartkem, Inc. (NASDAQ: SMTK)

SRx Health Solutions has acquired a 4.99% stake in Smartkem, Inc. as part of a strategic investment. This acquisition was made through a shelf take down and includes the purchase of convertible preferred securities. The company has filed a Registration Statement with the SEC related to this transaction, which will provide further details to shareholders.

Read more →
SRXH
May 29, 2026
SRXHGeneral

SRx Health Solutions Invests in Uber Technologies, Inc. and Provides Shareholders with Portfolio Update

SRx Health Solutions has updated its portfolio, initiating an investment in Uber Technologies, Inc. The company has also reduced its long position in Compass and trimmed its short exposure to Bitcoin, reflecting a cautious approach due to a shift in their EMJX stress model to STRESS. This marks the first negative market reading since the bull rotation began in April 2026.

Read more →

About SRX Global Inc.

North Palm Beach, FL 11 employees srxglobalinc.com
Headquarters801 US HIGHWAY 1, NORTH PALM BEACH, FL, 33408
BIOPHARMAWATCH ELITE
Trade the next SRXH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime